Selected Grantee Publications
- Clear All
- 253 results found
- Swine Models
- Nonhuman Primate Models
Elevated Inflammation Associated With Markers of Neutrophil Function and Gastrointestinal Disruption in Pilot Study of Plasmodium fragile Co-Infection of ART-Treated SIVmac239+ Rhesus Macaques
Nemphos et al., Viruses. 2024.
https://pubmed.ncbi.nlm.nih.gov/39066199/
Because of geographic overlap, a high potential exists for co-infection with HIV and malaria caused by Plasmodium fragile. Meta-analysis of data collected from 1991 to 2018 demonstrated co-incidence of these two infections to be 43%. Researchers used a male rhesus macaque (RM) model, 6–12 years of age, coinfected with P. fragile and antiretroviral (ART)-treated simian immunodeficiency virus (SIV) to mimic HIV/malaria co-infection observed in patients. ART-treated co-infected RMs demonstrated increased levels of inflammatory cytokines, shifts in neutrophil function, and gastrointestinal mucosal dysfunction. This model may be used to study molecular mechanisms of disease pathology and novel therapies, such as neutrophil-targeted interventions, for patients experiencing co-infection. Supported by ORIP (U42OD010568, U42OD024282, P51OD011104, R21OD031435) and NIGMS.
Transiently Boosting Vγ9+Vδ2+ γδ T Cells Early in Mtb Coinfection of SIV-Infected Juvenile Macaques Does Not Improve Mtb Host Resistance
Larson et al., Infection and Immunity. 2024.
https://pubmed.ncbi.nlm.nih.gov/39475292/
Children with HIV have a higher risk of developing tuberculosis (TB), which is caused by the bacterium Mycobacterium tuberculosis (Mtb). This study utilized juvenile Mauritian cynomolgus macaques to investigate whether enhancing Vγ9+Vδ2+ γδ T cells with zoledronate treatment could improve TB resistance in HIV–TB coinfection. Researchers found that although boosting these immune cells temporarily increased their presence, it did not enhance the macaques’ ability to fight Mtb infection. These findings suggest that solely targeting γδ T cells may not be an effective strategy for improving TB immunity in immunocompromised individuals. These insights are crucial for developing better treatments for HIV–TB coinfections. Supported by ORIP (K01OD033539, P51OD011106) and NIAID.
Three Novel Neoplasms in Nancy Ma's Owl Monkeys (Aotus nancymaae)
Bacon et al., Veterinary Pathology. 2024.
https://pubmed.ncbi.nlm.nih.gov/39692093/
Researchers have identified three previously unreported tumor types in male and female Nancy Ma’s owl monkeys (Aotus nancymaae), a nonhuman primate species that is rarely associated with tumors. Although past cases in owl monkeys were mostly linked to Herpesvirus saimiri–induced lymphoma, this research expands the understanding of tumor development in this species. These findings highlight potential new disease patterns and could inform veterinary care and biomedical research involving owl monkeys. Continued monitoring and investigation of tumors in New World primates are crucial for ensuring animal welfare and research integrity. Supported by ORIP (T32OD011083).
Transcriptomic and Genetic Profiling in a Spontaneous Non-Human Primate Model of Hypertrophic Cardiomyopathy and Sudden Cardiac Death
Rivas et al., Scientific Reports. 2024.
https://pubmed.ncbi.nlm.nih.gov/39733099/
Approximately 1 in 500 individuals are affected by hypertrophic cardiomyopathy (HCM). HCM is characterized by increased left ventricular wall thickness, diastolic dysfunction, and myocardial fibrosis. Outcomes of HCM range from arrhythmias and thromboembolic complications to sudden cardiac death. A current knowledge gap is in understanding the genetic cause of HCM. Researchers compared a nonhuman primate rhesus macaque HCM model to an adult human cohort data set and found that they shared 215 upregulated differentially expressed genes (DEGs); 40 downregulated DEGs; and enriched gene ontology terms, including cardiac muscle cell contraction and heart contraction. The molecular similarity in transcriptomic signatures could be used to develop novel drug therapies to treat HCM in patients. Supported by ORIP (P51OD011107, T32OD011147), NCATS, and NHLBI.
Lipid Nanoparticle-Mediated mRNA Delivery to CD34+ Cells in Rhesus Monkeys
Kim et al., Nature Biotechnology. 2024.
https://pubmed.ncbi.nlm.nih.gov/39578569
Blood cells, which are derived from hematopoietic stem cells (HSCs), promote pathologies including anemia, sickle cell disease, immunodeficiency, and metabolic disorders when dysfunctional. Because of the morbidity that results from the bone marrow mobilization and chemotherapy patient conditioning of current HSC therapies, novel treatment strategies that deliver RNA to HSCs are needed. Researchers found a lipid nanoparticle (LNP), LNP67, that delivers messenger RNA (mRNA) to murine HSCs in vivo and human HSCs ex vivo without the use of a cKit-targeting ligand. When tested in 7- to 8-month-old male and female rhesus monkeys, LNP67 successfully delivered mRNA to CD34+ cells and liver cells without adverse effects. These results show the potential translational relevance of an in vivo LNP–mRNA drug. Supported by ORIP (U42OD027094, P51OD011107), NIDDK, and NCATS.
Immune Gene Regulation Is Associated With Age and Environmental Adversity in a Nonhuman Primate
Watowich et al., Molecular Ecology. 2024.
https://pubmed.ncbi.nlm.nih.gov/39032090
The mammalian aging process involves a decline in physiological function, influenced by molecular mechanisms like epigenetic changes. These processes have been studied in controlled settings, however the role of aging in naturalistic populations remains unclear. This study explored the effects of environmental stressors (i.e., Hurricane Maria) on DNA methylation in free-living male and female rhesus macaques in Cayo Santiago, Puerto Rico. Results showed that environmental adversity accelerated age-related molecular changes, especially in gene transcription regions, while primary aging mainly affected nonregulatory regions. These findings highlight how the biology of aging is influenced by environmental factors. Supported by ORIP (P40OD012217), NIA, and NIMH.
SIV-Specific Antibodies Protect Against Inflammasome-Driven Encephalitis in Untreated Macaques
Castell et al., Cell Reports. 2024.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11552693
Viral infections are the most common infectious cause of encephalitis, and simian immunodeficiency virus (SIV)–infected macaques are a well-established model for HIV. Researchers investigated the protective effects of SIV-specific antibodies against inflammation-driven encephalitis in using untreated, SIV-infected, male and female pigtail and rhesus macaques. Findings indicate that these antibodies reduce neuroinflammation and encephalitis, highlighting the importance of antibodies in controlling neuroimmune responses, especially in the absence of antiretroviral therapy. This study provides insight into immune-modulatory approaches to combating inflammation-driven encephalopathies. Supported by ORIP (U42OD013117, T32OD011089), NIDA, NHLBI, NIAID, NINDS, and NIMH.
Potent Broadly Neutralizing Antibodies Mediate Efficient Antibody-Dependent Phagocytosis of HIV-Infected Cells
Snow et al., PLOS Pathogens. 2024.
https://pubmed.ncbi.nlm.nih.gov/39466835
This study investigates the role of potent broadly neutralizing antibodies (bNAbs) in mediating antibody-dependent cellular phagocytosis (ADCP) of HIV-infected cells. Researchers developed a novel cell-based approach to assess the ADCP of HIV-infected cells expressing natural conformations of the viral envelope glycoprotein, which allows the virus to infect a host cell. The findings in this study demonstrate that bNAbs facilitate efficient ADCP, highlighting their potential in controlling HIV infection by promoting immune clearance of infected cells. This study provides valuable insights into antibody-mediated immune mechanisms and supports the development of antibody-based therapies and vaccines targeting HIV. Supported by ORIP (P51OD011106) and NIAID.
SHIV Remission in Macaques With Early Treatment Initiation and Ultra Long-Lasting Antiviral Activity
Daly et al., Nature Communications. 2024.
https://pubmed.ncbi.nlm.nih.gov/39632836
Antiretroviral therapy (ART) suppresses HIV and simian immunodeficiency virus (SIV) replication but cannot eliminate reservoirs of long-lived infected cells that enable rebound after discontinuation of ART. These researchers hypothesized that ART designed to have long-lasting activity and penetrate tissue reservoirs would be optimized against HIV or SIV remission. Macaques were treated with a four-drug regimen (i.e., oral emtricitabine/tenofovir alafenamide and long-acting cabotegravir/rilpivirine) designed to improve dosing of immune cells, with or without the immune-activating drug vesatolimod (VES), after the onset of SIV viremia. The animals were monitored for 1 year with treatment and 2 additional years following treatment discontinuation. Durable viral suppression was observed in all animals treated with the optimized ART regimen with or without VES. These results will inform novel HIV treatment regimens with long-lasting antiviral activity in humans. Supported by ORIP (P40OD028116).
A Single-Dose Intranasal Live-Attenuated Codon Deoptimized Vaccine Provides Broad Protection Against SARS-CoV-2 and Its Variants
Liu et al., Nature Communications. 2024.
https://pubmed.ncbi.nlm.nih.gov/39187479
Researchers developed an intranasal, single-dose, live-attenuated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) vaccine (CDO-7N-1) using codon deoptimization. This vaccine demonstrates broad protection against SARS-CoV-2 variants, with highly attenuated replication and minimal lung pathology across multiple in vivo passages. The vaccine induced robust mucosal and systemic neutralizing antibodies, as well as T-cell responses, in male and female hamsters, female K18-hACE2 mice, and male HFH4-hACE2 mice. In male and female cynomolgus macaques, CDO-7N-1 effectively prevented infection, reduced severe disease, and limited transmission of SARS-CoV-2 variants. This innovative approach offers potential advantages over traditional spike-protein vaccines by providing durable protection and targeting emerging variants to curb virus transmission. Supported by ORIP (K01OD026529).